EUVIMEDEUVIMED entdecken
Crossref

Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer

Lei Fang, Ruixue Zhu, Meijing Li, Junhui Ma, Sijun Fan, Xuelian He, Zhongrui Yang, Yakai Yan, Xiang Ma, Guangya Xiang

European Journal of Pharmaceutics and Biopharmaceutics · 2025-05 · 210 · 114699

DOI: 10.1016/j.ejpb.2025.114699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025-05. Verfasst von Lei Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Silicon Dioxide, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis targeting chimeras (PROTACs) technology is a promising strategy for degrading proteins of interest. Traditional PROTACs, however, often face challenges such as poor solubility, low stability, and off-target toxicity. To address these challenges, we integrated nanotechnology to enhance the delivery of target-protein degraders to the tumor sites, thereby improving their properties. Here, we report silica-based nano-PROTACs (SiPROTACs) that feature multiple ligands on the surface to target and degrade the transmembrane protein epidermal growth factor receptor (EGFR). SiPROTACs, with a diameter of approximately 50 nm, can efficiently bind to EGFR, recruit cereblon (CRBN) to induce EGFR ubiquitination, and facilitate their degradation by proteasomes. In HCC-827 and PC-9 cell lines, SiPROTACs initiated EGFR degradation at a notably low concentration of 50 nM, demonstrating greater efficiency compared to traditional PROTACs. In HCC-827 xenograft tumor-bearing mice, SiPROTACs accumulated at tumor site for at least 48 h and exhibited significant anti-tumor effects in vivo without causing noticeable side effects. These findings suggest a novel approach for the application of PROTACs highlighting their therapeutic potential for the treatment of non-small cell lung cancer (NSCLC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungSilicon DioxideErbB ReceptorsLung NeoplasmsNanoparticlesAntineoplastic AgentsAnimalsHumansMiceCell Line, TumorProteolysisXenograft Model Antitumor AssaysMice, NudeDrug Delivery SystemsMice, Inbred BALB C

Stichwörter der Autor:innen

Nano-PROTACsNon-small cell lung cancerTargeted protein degradation

Substanzen

Silicon DioxideErbB ReceptorsEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Departement of Pharmacy, Tongren Polytechnic College, Tongren 554300, China. Electronic address: xiangma@hu…
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Departement of Pharmacy, Tongren Polytechnic College, Tongren 554300, China; Institute of the Higher Educat…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fang, L., Zhu, R., Li, M., Ma, J., Fan, S., He, X., Yang, Z., Yan, Y., Ma, X., & Xiang, G. (2025). Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics, 210, 114699. https://doi.org/10.1016/j.ejpb.2025.114699

Vancouver

Fang L, Zhu R, Li M, Ma J, Fan S, He X, et al. Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics. 2025;210:114699. doi:10.1016/j.ejpb.2025.114699

BibTeX
@article{Fang2025,
  author = {Fang, Lei and Zhu, Ruixue and Li, Meijing and Ma, Junhui and Fan, Sijun and He, Xuelian and Yang, Zhongrui and Yan, Yakai and Ma, Xiang and Xiang, Guangya},
  title = {Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2025},
  volume = {210},
  pages = {114699},
  doi = {10.1016/j.ejpb.2025.114699}
}
Kostenlos starten →